Inovio Pharmaceuticals In... (INO)
Inovio Pharmaceuticals Statistics
Share Statistics
Inovio Pharmaceuticals has 36.67M shares outstanding. The number of shares has increased by 41.51% in one year.
| Shares Outstanding | 36.67M |
| Shares Change (YoY) | 41.51% |
| Shares Change (QoQ) | 1.57% |
| Owned by Institutions (%) | 47.43% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 15,720 |
| FTD / Avg. Volume | 2.32% |
Short Selling Information
The latest short interest is 6.68M, so 18.22% of the outstanding shares have been sold short.
| Short Interest | 6.68M |
| Short % of Shares Out | 18.22% |
| Short % of Float | 18.3% |
| Short Ratio (days to cover) | 8.55 |
Valuation Ratios
The PE ratio is -0.46 and the forward PE ratio is -0.87. Inovio Pharmaceuticals's PEG ratio is 0.01.
| PE Ratio | -0.46 |
| Forward PE | -0.87 |
| PS Ratio | 228.26 |
| Forward PS | 0.2 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Inovio Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.77, with a Debt / Equity ratio of 0.17.
| Current Ratio | 2.77 |
| Quick Ratio | 2.77 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | -114.15 |
| Debt / FCF | -0.11 |
| Interest Coverage | -632.05 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,625.04 |
| Profits Per Employee | $-800,403.93 |
| Employee Count | 134 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -107.15B |
| Effective Tax Rate | 99.9% |
Stock Price Statistics
The stock price has increased by -84.35% in the last 52 weeks. The beta is 1.84, so Inovio Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.84 |
| 52-Week Price Change | -84.35% |
| 50-Day Moving Average | 1.85 |
| 200-Day Moving Average | 4.37 |
| Relative Strength Index (RSI) | 55.61 |
| Average Volume (20 Days) | 677,773 |
Income Statement
In the last 12 months, Inovio Pharmaceuticals had revenue of 217.76K and earned -107.25M in profits. Earnings per share was -3.95.
| Revenue | 217.76K |
| Gross Profit | -2.91M |
| Operating Income | -112.4M |
| Net Income | -107.25M |
| EBITDA | -103.95M |
| EBIT | -107.08M |
| Earnings Per Share (EPS) | -3.95 |
Balance Sheet
The company has 65.81B in cash and 11.87B in debt, giving a net cash position of 53.95B.
| Cash & Cash Equivalents | 65.81B |
| Total Debt | 11.87B |
| Net Cash | 53.95B |
| Retained Earnings | -1,730.2B |
| Total Assets | 113.2M |
| Working Capital | 62.5M |
Cash Flow
In the last 12 months, operating cash flow was -104.08M and capital expenditures 0, giving a free cash flow of -104.08B.
| Operating Cash Flow | -104.08M |
| Capital Expenditures | n/a |
| Free Cash Flow | -104.08B |
| FCF Per Share | -3831.86 |
Margins
Gross margin is -1337.41%, with operating and profit margins of -51616.91% and -49254.27%.
| Gross Margin | -1337.41% |
| Operating Margin | -51616.91% |
| Pretax Margin | -49254269% |
| Profit Margin | -49254.27% |
| EBITDA Margin | -47735.19% |
| EBIT Margin | -51616.91% |
| FCF Margin | -47795033.43% |
Dividends & Yields
INO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for INO is $16.5, which is 777.7% higher than the current price. The consensus rating is "Buy".
| Price Target | $16.5 |
| Price Target Difference | 777.7% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Jan 25, 2024. It was a backward split with a ratio of 1:12.
| Last Split Date | Jan 25, 2024 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | -22.93 |
| Piotroski F-Score | 1 |